Ultomiris (Ravulizumab)
- Medicine Name: Ultomiris
- Generic Name: Ravulizumab
- Dosage Form & Strength: Injection: 300 mg/30 mL (10 mg/mL) in a single-dose vial
- Manufactured By: Alexion Pharmaceuticals, Inc.
Medical Uses
Ultomiris is a complement inhibitor used for:
- The treatment of adult and pediatric patients aged one month and older with paroxysmal nocturnal hemoglobinuria (PNH).
- The treatment of adult and pediatric patients aged one month and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA)
Recommended Dosage: The recommended dosing regimen in adult and pediatric patients, aged one month or older weighing 5 kg or greater, with PNH and aHUS consists of a loading dose followed by maintenance dosing, administered by intravenous infusion. The dosing is based on the patient’s body weight. Starting 2 weeks after the loading dose administration, begin maintenance doses once every 4 or 8 weeks, based on body weight.
The dosing schedule is allowed to occasionally vary within one week of the scheduled infusion day (except for the 1’st maintenance dose of ultomiris injection); but the subsequent doses should be used as per the original schedule.
Recommended dosage for Patients with Body Weight Range (kg):
- 5 to less than 10 kg: 600 mg (Loading Dose); 300 mg maintenance dose for every 4 weeks.
- 10 to less than 20 kg: 600 mg (Loading Dose); 600 mg maintenance dose for every 4 weeks.
- 20 to less than 30 mg: 900 mg (Loading Dose); 2,100 mg maintenance dose for every 8 weeks.
- 30 to less than 40 mg: 1,200 mg (Loading Dose); 2,700 mg maintenance dose for every 8 weeks.
- 40 to less than 60 mg: 2,400 mg (Loading Dose); 3,000 mg maintenance dose for every 8 weeks.
- 60 to less than 100 mg: 2,700 mg (Loading Dose); 3,300 mg maintenance dose for every 8 weeks.
- 100 kg or greater: 3,000 mg (Loading Dose); 3,600 mg maintenance dose for every 8 weeks.
Warning & Precautions
- Hazardous meningococcal infections have been seen in patients treated with Ravulizumab. The use of this medicine increases a patient’s risk to catch serious meningococcal infections (septicemia/meningitis). Meningococcal disease because of any serogroup may emerge.
- Immunize patients without a known history of meningococcal vaccination at least 14 days prior to their first Ultomiris dose. If urgent ultomiris 10 mg/ml therapy is needed in an unvaccinated patient, administer meningococcal vaccine(s) as quickly as possible and provide patients with 14 days of antibacterial drug prophylaxis.
- Precisely monitor patients for early signs/symptoms of meningococcal infection and assess patients promptly in case infection is suspected. Inform patients of these signs/symptoms and steps to be considered to seek prompt medical care. Meningococcal infection may quickly become life-threatening or fatal in case not identified and treated early.
- After discontinuing therapy with ultomiris 300 mg/30 ml, closely monitor for signs/symptoms of hemolysis, identified by elevated LDH together with sudden reduction in PNH clone size or hemoglobin, or occurrence of symptoms such as abdominal pain, fatigue, shortness of breath (dyspnea), hemoglobinuria, major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction.
- Use of Ravulizumab injection may result in infusion-related reactions including anaphylaxis and hypersensitivity reactions. These reactions typically do not require interruption of therapy. Interrupt the Ravulizumab infusion and institute apt supportive measures in case signs/symptoms of cardiovascular instability or respiratory compromise appear.
Documentation & Availability
What documents are required to import ULTOMIRIS to India?
ULTOMIRIS (ravulizumab) injection can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is ULTOMIRIS available in India?
ULTOMIRIS (ravulizumab injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). S S Healthcare is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
ULTOMIRIS can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
S S Healthcare (S S Healthcare) can facilitate the supply of ULTOMIRIS (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-7575883015 | Toll-Free No: +91-7575883015 or write us at sshealthcare1012@gmail.com for ultomiris price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
S S Healthcare is able to source the ULTOMIRIS (Cancer Treatment Medicines) from across the globe, and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Ultomiris®?
Ravulizumab is Generic Name for the trade name drug Ultomiris®.
What is the Manufacturer Name of Ultomiris®?
Ultomiris® is manufactured by Alexion Pharmaceuticals, Inc.
Is Ultomiris® approved by the FDA?
Yes, Ultomiris® is approved by the FDA. Date of first approval: December 21, 2018.
What is the dosage and form of Ultomiris® supplied?
Ultomiris® is supplied as an Injection in three different dosage strength:
- 300 mg/30 mL (10 mg/mL) in a single-dose vial.
- 300 mg/3 mL (100 mg/mL) in a single-dose vial.
- 1,100 mg/11 mL (100 mg/mL) in a single-dose vial.
What are the most common side effects due to Ultomiris®?
Most common side effects due to Ultomiris® in patients with PNH include: upper respiratory tract infection, headache; and in patients with aHUS include diarrhea, upper respiratory tract infection, nausea, hypertension vomiting, headache, and pyrexia
How much does Ripretinib cost in India?
The ultomiris cost in India is very reasonable and can vary. To procure this complement inhibitor authentically, you can call or WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com.
What are the storage conditions of Ultomiris®?
Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton in order to protect from light. Neither freeze nor shake.
Is it safe to buy Ultomiris® online from India?
Yes, You can buy ultomiris injection from India online authentically from https://www.indianpharmanetwork.in/ if Ultomiris is not available or has not been approved in your home country.
What are the Highlights of prescribing information for Ultomiris®?
Click Here to download full Ultomiris prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
